US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biotechnology

65.71

+0.25000.38%

Number of Gainers:296

Number of Losers:220

Number of Flat:13

PE:- -

High:66.13

Open:65.46

Low:65.21

Close:65.46

Volume:668.90M

Turnover:13.85B

Market Cap:1.72T

Float Cap:1.54T

Loading ...

Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks

Arcus Biosciences Is Maintained at Buy by Citigroup

Why Is Scholar Rock Stock Trading Lower On Monday?

Benzinga_recent_news

Analysts’ Top Healthcare Picks: Cabaletta Bio (CABA), Icon (ICLR)

Compass Pathways Is Maintained at Buy by BTIG

Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss

Benzinga_recent_news

Nuvalent Inc. Announces New Preclinical Data on HER2-Selective Inhibitor NVL-330 to Be Presented at AACR-NCI-EORTC Conference

Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations

Radiopharm Theranostics trading resumes

WHO issues alert over contaminated cough syrups in India

Actinium Pharmaceuticals Unveils Preclinical Data Showing ATNM-400 Overcomes Osimertinib Resistance in EGFR-Mutated NSCLC at AACR-NCI-EORTC Conference

Regeneron Pharma Is Maintained at Buy by Citigroup

Anbio Biotechnology falls -5.5%

Promising Phase 3 Results for BriaCell’s Bria-IMT in Metastatic Breast Cancer

Adlai Nortye to Present Promising Data on Novel CEACAM5-Targeting ADC AN4035 at Major Cancer Conference

Genmab A/S Stock Rises Monday, Outperforms Market

Merus NV to Present Promising Phase 2 Data for Petosemtamab in Metastatic Colorectal Cancer at Major Oncology Conference

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires Live

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for Rinvoq® (Upadacitinib) for the Treatment of Inflammatory Bowel Disease

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4139/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4139","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4139\",,,,,undefined,":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":65.70506,"timestamp":1760385599999,"preClose":65.45504,"halted":0,"volume":668898159,"delay":0,"changeRate":0.00382,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":0.250023,"latestTime":"10-13 16:00:00 EDT","open":65.455055,"high":66.13199,"low":65.2087,"amount":13851133899.960707,"amplitude":0.014106,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1760400000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.725041,"peRate":-105.418727,"turnoverRate":0.0213,"increases":296,"decrements":220,"flats":11,"marketCap":1716725214235,"floatMarketCap":1539173626947.3281},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4139\",,,,,undefined,":{"symbol":"BK4139","high":66.13199,"amplitude":0.014106,"preClose":65.45504,"low":65.2087,"pbRate":"6.725041","latestPrice":65.70506,"volume":668898159,"delay":0,"open":65.455055,"prevYearClose":54.762566,"prevWeekClose":65.455,"prevMonthClose":63.8033,"prevQuarterClose":63.8033,"fiveDayClose":65.4038,"twentyDayClose":61.6226,"sixtyDayClose":57.0252,"secType":"PLATE","market":"US","turnoverRate":0.0213,"peRate":-105.418727,"marketCap":1716725214235,"floatMarketCap":1539173626947.3281,"timestamp":1760385599999,"nameCN":"Biotechnology"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4139\",,,,undefined,":{"bkCode":"BK4139","up":296,"down":220,"flat":13},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4139\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575328444","title":"Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks","url":"https://stock-news.laohu8.com/highlight/detail?id=2575328444","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575328444?lang=en_us&edition=fundamental","pubTime":"2025-10-14 02:23","pubTimestamp":1760379780,"startTime":"0","endTime":"0","summary":"Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and placebo response.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/13/Medical--Research-And-Scientist-In-Labor_0.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/13/Medical--Research-And-Scientist-In-Labor_0.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/10/48184263/tvardi-therapeutics-lung-disease-candidate-fails-to-show-any-clinical-benefit-stock-sinks","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48184263/tvardi-therapeutics-lung-disease-candidate-fails-to-show-any-clinical-benefit-stock-sinks","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4539","FVC","BK4139","LENZ","TVRD","BK4007"],"gpt_icon":0},{"id":"2575986281","title":"Arcus Biosciences Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2575986281","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575986281?lang=en_us&edition=fundamental","pubTime":"2025-10-14 01:58","pubTimestamp":1760378280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RCUS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 13, 2025 13:58 ET (17:58 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCUS"],"gpt_icon":0},{"id":"2575819832","title":"Why Is Scholar Rock Stock Trading Lower On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2575819832","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575819832?lang=en_us&edition=fundamental","pubTime":"2025-10-14 01:52","pubTimestamp":1760377920,"startTime":"0","endTime":"0","summary":"Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservation in trial.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/13/Scholar-Rock.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/13/Scholar-Rock.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/25/10/48183276/why-is-scholar-rock-stock-trading-lower-on-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/25/10/48183276/why-is-scholar-rock-stock-trading-lower-on-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4532","BK4530","BK4139","LU1093756325.SGD","BK4588","BK4121","LU1815336091.USD","SRRK","SMA","LU1093756168.USD","BK4585","BK4217","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4007","IE00BKVL7J92.USD","BK4599","CRL","LU0757428866.USD","LU0390134368.USD"],"gpt_icon":1},{"id":"2575811442","title":"Analysts’ Top Healthcare Picks: Cabaletta Bio (CABA), Icon (ICLR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2575811442","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575811442?lang=en_us&edition=fundamental","pubTime":"2025-10-14 01:50","pubTimestamp":1760377836,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cabaletta Bio (CABA – Research Report) and Icon (ICL...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-cabaletta-bio-caba-icon-iclr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-cabaletta-bio-caba-icon-iclr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0528227936.USD","LU2362541273.HKD","LU1791710582.SGD","LU0057025933.USD","BK4585","LU1983260115.SGD","LU0114720955.EUR","LU0426412945.USD","BK4121","LU0175139822.USD","BK4532","LU1267930573.SGD","LU1267930813.SGD","LU2324357040.USD","XLV","BK4588","LU0708994859.HKD","LU0792757196.USD","XBI","LU0511384066.AUD","LU0069063385.USD","LU1043141123.HKD","LU1691799644.USD","LU0426417589.USD","LU0187121727.USD","LU1121112475.USD","LU0128525929.USD","LU0029864427.USD","LU0289960550.SGD","LU1043141396.HKD","LU0310800379.SGD","HCSG","LU0289961442.SGD","LU0994945656.USD","BK4581","ICLR","LU2244417387.USD","LU0882574055.USD","CABA","LU1791710400.SGD","LABU","LU0472753341.HKD","LU2265009873.SGD","LU0289739343.SGD","LU0728928796.USD","LU2362540622.SGD","LU0889566641.SGD","LU1804176565.USD","BK4139","LU2362541513.USD"],"gpt_icon":0},{"id":"2575891512","title":"Compass Pathways Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2575891512","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575891512?lang=en_us&edition=fundamental","pubTime":"2025-10-14 01:28","pubTimestamp":1760376480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 13, 2025 13:28 ET (17:28 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"gpt_icon":0},{"id":"2575289780","title":"Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2575289780","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575289780?lang=en_us&edition=fundamental","pubTime":"2025-10-14 01:24","pubTimestamp":1760376240,"startTime":"0","endTime":"0","summary":"Regeneron gene therapy for OTOF-related hearing loss shows rapid, sustained improvements, including normal hearing in some participants.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/13/Tarrytown--Ny---March-21--2020---This-We.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/13/Tarrytown--Ny---March-21--2020---This-We.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/10/48182533/regeneron-gene-therapy-shows-significant-hearing-gains-in-genetic-hearing-loss","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48182533/regeneron-gene-therapy-shows-significant-hearing-gains-in-genetic-hearing-loss","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0320765992.SGD","PTA","LU0889565916.HKD","LU2362541273.HKD","LU0823416689.USD","BK4588","LU2106854487.HKD","ABR","LU0823434740.USD","LU2237438978.USD","LU0109394709.USD","REGN","LU0823434583.USD","BK4585","LU2362541513.USD","BK4139","LU2468319806.SGD","LU0289739699.SGD","LU0114720955.EUR","LU2089984988.USD","LU0053666078.USD","BK4110","LU2362540622.SGD","LU2023250504.SGD","LU1917777945.USD","LU0058720904.USD","LU1974910355.USD","LU0882574055.USD"],"gpt_icon":0},{"id":"2575286930","title":"Nuvalent Inc. Announces New Preclinical Data on HER2-Selective Inhibitor NVL-330 to Be Presented at AACR-NCI-EORTC Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575286930","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575286930?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:53","pubTimestamp":1760374414,"startTime":"0","endTime":"0","summary":"Nuvalent Inc. Announces New Preclinical Data on HER2-Selective Inhibitor NVL-330 to Be Presented at AACR-NCI-EORTC Conference. Nuvalent Inc., a clinical-stage biopharmaceutical company, has announced an upcoming poster presentation highlighting new preclinical data for its novel HER2-selective inhibitor, NVL-330. The presentation will further characterize the preclinical intracranial activity of NVL-330. The data will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston. The poster session is set for October 24, 2025. Results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvalent Inc. published the original co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL8N4Tz8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","NUVL"],"gpt_icon":0},{"id":"2575428611","title":"Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations","url":"https://stock-news.laohu8.com/highlight/detail?id=2575428611","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575428611?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:46","pubTimestamp":1760373960,"startTime":"0","endTime":"0","summary":"Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented at ESMO 2025.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/13/Lung-cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/13/Lung-cancer.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/10/48181455/cullinan-therapeutics-cancer-drug-shows-efficacy-in-brain-metastases-among-lung-cancer-patients-with-certain-mutations","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/10/48181455/cullinan-therapeutics-cancer-drug-shows-efficacy-in-brain-metastases-among-lung-cancer-patients-with-certain-mutations","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["CNS","CGEM","BK4139","BK4135","ORR"],"gpt_icon":0},{"id":"2575286493","title":"Radiopharm Theranostics trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2575286493","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575286493?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:40","pubTimestamp":1760373607,"startTime":"0","endTime":"0","summary":"12:40 EDT Radiopharm (RADX) Theranostics trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/radiopharm-theranostics-trading-resumes-thefly-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/radiopharm-theranostics-trading-resumes-thefly-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RADX"],"gpt_icon":0},{"id":"2575854992","title":"WHO issues alert over contaminated cough syrups in India","url":"https://stock-news.laohu8.com/highlight/detail?id=2575854992","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575854992?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:21","pubTimestamp":1760372513,"startTime":"0","endTime":"0","summary":"WHO issues alert over contaminated cough syrups in IndiaOct 13  - The World Health Organization issued an alert on Monday identifying three contaminated cough syrups in India that can cause severe, potentially life-threatening illness.The health agency said the affected medicines are specific batches of COLDRIF, Respifresh TR and ReLife, manufactured by Sresan Pharmaceutical, Rednex Pharmaceuticals and Shape Pharma.  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL3N3VU138:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TLOG"],"gpt_icon":0},{"id":"2575855662","title":"Actinium Pharmaceuticals Unveils Preclinical Data Showing ATNM-400 Overcomes Osimertinib Resistance in EGFR-Mutated NSCLC at AACR-NCI-EORTC Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575855662","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575855662?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:11","pubTimestamp":1760371868,"startTime":"0","endTime":"0","summary":"Actinium Pharmaceuticals Unveils Preclinical Data Showing ATNM-400 Overcomes Osimertinib Resistance in EGFR-Mutated NSCLC at AACR-NCI-EORTC Conference. Actinium Pharmaceuticals Inc. announced that the first preclinical data from its ATNM-400 program in non-small cell lung cancer  has been accepted for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025. ATNM-400 is a first-in-class Actinium-225 antibody radioconjugate with demonstrated preclinical activity in both prostate cancer and NSCLC. The new findings indicate that ATNM-400 can overcome resistance to the EGFR inhibitor osimertinib in EGFR-mutated NSCLC, addressing a significant unmet clinical need. The results will be presented during Poster Session C on October 25, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL66WzFx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ATNM"],"gpt_icon":0},{"id":"2575285819","title":"Regeneron Pharma Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2575285819","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575285819?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:07","pubTimestamp":1760371620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 13, 2025 12:07 ET (16:07 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU2089984988.USD","LU2237438978.USD","REGN","LU2362541273.HKD","BK4588","LU0823434583.USD","LU0882574055.USD","LU2023250504.SGD","LU0053666078.USD","LU0823434740.USD","LU0109394709.USD","LU1917777945.USD","LU0823416689.USD","BK4139","LU0058720904.USD","LU2362541513.USD","LU0114720955.EUR","LU1974910355.USD","LU0320765992.SGD","LU2106854487.HKD","LU2362540622.SGD","LU0889565916.HKD","BK4585","LU2468319806.SGD"],"gpt_icon":0},{"id":"2575129285","title":"Anbio Biotechnology falls -5.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575129285","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575129285?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:05","pubTimestamp":1760371555,"startTime":"0","endTime":"0","summary":"Anbio Biotechnology (NNNN) is down -5.5%, or -$1.65 to $28.20. Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/anbio-biotechnology-falls-5-5-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/anbio-biotechnology-falls-5-5-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NNNN","BK4139"],"gpt_icon":0},{"id":"2575854332","title":"Promising Phase 3 Results for BriaCell’s Bria-IMT in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2575854332","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575854332?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:05","pubTimestamp":1760371511,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maint...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-phase-3-results-for-briacells-bria-imt-in-metastatic-breast-cancer-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-phase-3-results-for-briacells-bria-imt-in-metastatic-breast-cancer-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4588","XBI","BK4585","BCTX","LABU","BK4139","BK4581"],"gpt_icon":0},{"id":"2575099283","title":"Adlai Nortye to Present Promising Data on Novel CEACAM5-Targeting ADC AN4035 at Major Cancer Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575099283","media":"Reuters","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575099283?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:02","pubTimestamp":1760371369,"startTime":"0","endTime":"0","summary":"Adlai Nortye Ltd. has announced that it will deliver an oral presentation on its novel drug candidate AN4035 at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, MA. The presentation, titled \"Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate  armed with a proprietary pan-RAS inhibitor payload, designed to broaden the therapeutic window,\" is set for October 25, 2025. Further scientific details and data highlights will be released following the public posting of the abstract on the AACR portal on October 22, 2025. The results of the study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nort","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL6vCB78:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ199S13.USD","BK4139","ANL","LU2133065610.SGD"],"gpt_icon":0},{"id":"2575283030","title":"Genmab A/S Stock Rises Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2575283030","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575283030?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:01","pubTimestamp":1760371260,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Genmab A/S rose 1.6% to DKK2,077.00 Monday on what proved to be an overall poor trading session for the stock market, with the OMX Nordic 40 Index falling 0.2% to 2,374.64.The stock's rise  snapped a two-day losing streak.The company closed DKK67.00 short of its 52-week high of DKK2,144.00, which the company achieved on October 6, 2025.Trading volume was 103,783, compared to the 50-day average trading volume of 152,624.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB","BK6045","BK4139","BK6520","MR7.SI"],"gpt_icon":0},{"id":"2575837172","title":"Merus NV to Present Promising Phase 2 Data for Petosemtamab in Metastatic Colorectal Cancer at Major Oncology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575837172","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575837172?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:00","pubTimestamp":1760371227,"startTime":"0","endTime":"0","summary":"Merus N.V. has announced the upcoming presentation of initial interim data from a phase 2 trial evaluating petosemtamab, a bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer . The data, which assess petosemtamab in combination with standard chemotherapy in first- and second-line mCRC and as monotherapy in heavily pretreated  mCRC, will be presented during a plenary session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The plenary session is scheduled for Friday, October 24, 2025, from 10:00 to 11:40 a.m. ET. Additionally, Merus will present a poster on the preclinical evaluation of petosemtamab on cancer stem cells during Poster Session B, held on the same day from 12:30 to 4:00 p.m. ET. The abstracts will be available in the conference app starting Wednesday, October 22, 2025, at 12:00 p.m. ET, and full presentations are planned for availability on the Merus website at the start of each session.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDLxj2xP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","NDAQ","LU0320765992.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0109394709.USD","LU2095319765.USD","LU0314104364.USD","MRUS","IE00BKPKM429.USD","BK4588","BK4112","LU0889565916.HKD","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139"],"gpt_icon":0},{"id":"2575228307","title":"Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2575228307","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575228307?lang=en_us&edition=fundamental","pubTime":"2025-10-14 00:00","pubTimestamp":1760371200,"startTime":"0","endTime":"0","summary":"- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m. ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165684/37568/en/Merus-Announces-Petosemtamab-in-Metastatic-Colorectal-Cancer-Abstract-Selected-for-Plenary-Session-Oral-Presentation-at-the-AACR-NCI-EORTC-International-Conference-on-Molecular-Tar.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1550","LU0572940350.SGD","LU0264606111.USD","BK4539","LU0572939691.SGD","BK1184","01336","LENZ","BK1584","NCI","BK4139","BK4007","BK4202"],"gpt_icon":0},{"id":"2575288616","title":"European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2575288616","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575288616?lang=en_us&edition=fundamental","pubTime":"2025-10-13 23:09","pubTimestamp":1760368188,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts opened the week higher late Monday morning, rising 0.94% to 1,560.11 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and biotech firm Evaxion , which climbed 9.2% and 3.4%, respectively. They were followed by semiconductor company Sequans Communications  and 3D printer company Materialise , which advanced 2.7% and 2.4%, respectively.The decliners from continental Europe were led by biopharmaceutical company Genfit  and telecommunications company Nokia , which fell 1.5% each. They were followed by internet advertising firm Criteo  and medical device maker EDAP TMS , which lost 1.4% and 1%, respectively.From the UK and Ireland, the gainers were led by biopharmaceutical companies NuCana  and Adaptimmune Therapeutics , which surged 15% and 10%, respectively. They were followed by pharmaceutical company Silence Therapeutics  and biopharmaceutical compan","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","BTI.AU","BK4547","BK4588","BCYC","IE00BMPRXN33.USD","BK4546","BK4020","NCNA","TRIB","SQNS","AFG","IE00BMPRXR70.SGD","BK4139","CRTO","BK4075","BTI","SLN","NOK","EVAX","LU0006061336.USD","ADAP","BK7062","BDRX","IE00BFMHRM44.USD","CLLS","BK4117","AMRN","EDAP","BK4585","BK4141","GNFT","BK4009","LU2543165471.USD","MTLS","BK4023","BK4107"],"gpt_icon":0},{"id":"2575002774","title":"U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for Rinvoq® (Upadacitinib) for the Treatment of Inflammatory Bowel Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2575002774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575002774?lang=en_us&edition=fundamental","pubTime":"2025-10-13 22:58","pubTimestamp":1760367490,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUA6DTXBM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJT1NW94.SGD","LU0456855351.SGD","LU2129689431.USD","IE00BGHQF631.EUR","BK4550","LU1093756168.USD","LU0203345920.USD","LU2237443622.USD","LU2237443978.SGD","LU2129689514.USD","LU2112291526.USD","LU2089984988.USD","LU1496350502.SGD","LU1934455194.USD","LU2237443465.HKD","LU0320765646.SGD","LU0985320562.USD","BK4139","ABBV","LU1037948897.HKD","LU0432979614.USD","LU0820561909.HKD","LU1496350171.SGD","LU0256863811.USD","LU0689472784.USD","LU0965508806.USD","LU1934455277.USD","IE00BDGV0183.EUR","LU0310799852.SGD","IE00B19Z3581.USD","LU1585245621.USD","LU0158827948.USD","LU1839511570.USD","LU0256863902.USD","LU1037948541.HKD","LU0198837287.USD","LU0310800379.SGD","BK4559","IE00B3PB1722.GBP","LU0203347892.USD","LU2089284900.SGD","LU0234570918.USD","IE00BJJMRZ35.SGD","BK4566","IE00B4R5TH58.HKD","LU0545039389.USD","LU0661504455.SGD","LU0820561818.USD","LU1162221912.USD","LU2129689605.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":105,"pageCount":1,"totalSize":2089,"code":"91000000","status":"200"}]}}